Cargando…

Investigation of Leoligin Derivatives as NF-κΒ Inhibitory Agents

The transcription factor NF-κB is an essential mediator of inflammation; thus, the identification of compounds that interfere with the NF-κB signaling pathway is an important topic. The natural products leoligin and 5-methoxyleoligin have served as a starting point for the development of NF-κB inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Linder, Thomas, Papaplioura, Eleni, Ogurlu, Diyana, Geyrhofer, Sophie, Hummelbrunner, Scarlet, Schachner, Daniel, Atanasov, Atanas G., Mihovilovic, Marko D., Dirsch, Verena M., Schnürch, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773117/
https://www.ncbi.nlm.nih.gov/pubmed/35052742
http://dx.doi.org/10.3390/biomedicines10010062
_version_ 1784636003952099328
author Linder, Thomas
Papaplioura, Eleni
Ogurlu, Diyana
Geyrhofer, Sophie
Hummelbrunner, Scarlet
Schachner, Daniel
Atanasov, Atanas G.
Mihovilovic, Marko D.
Dirsch, Verena M.
Schnürch, Michael
author_facet Linder, Thomas
Papaplioura, Eleni
Ogurlu, Diyana
Geyrhofer, Sophie
Hummelbrunner, Scarlet
Schachner, Daniel
Atanasov, Atanas G.
Mihovilovic, Marko D.
Dirsch, Verena M.
Schnürch, Michael
author_sort Linder, Thomas
collection PubMed
description The transcription factor NF-κB is an essential mediator of inflammation; thus, the identification of compounds that interfere with the NF-κB signaling pathway is an important topic. The natural products leoligin and 5-methoxyleoligin have served as a starting point for the development of NF-κB inhibitors. Using our modular total synthesis method of leoligin, modifications at two positions were undertaken and the effects of these modifications on the biological activity were investigated. The first modification concerned the ester functionality, where it was found that variations in this position have a significant influence, with bulky esters lacking Michael-acceptor properties being favored. Additionally, the substituents on the aryl group in position 2 of the tetrahydrofuran scaffold can vary to some extent, where it was found that a 3,4-dimethoxy and a 4-fluoro substitution pattern show comparable inhibitory efficiency.
format Online
Article
Text
id pubmed-8773117
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87731172022-01-21 Investigation of Leoligin Derivatives as NF-κΒ Inhibitory Agents Linder, Thomas Papaplioura, Eleni Ogurlu, Diyana Geyrhofer, Sophie Hummelbrunner, Scarlet Schachner, Daniel Atanasov, Atanas G. Mihovilovic, Marko D. Dirsch, Verena M. Schnürch, Michael Biomedicines Article The transcription factor NF-κB is an essential mediator of inflammation; thus, the identification of compounds that interfere with the NF-κB signaling pathway is an important topic. The natural products leoligin and 5-methoxyleoligin have served as a starting point for the development of NF-κB inhibitors. Using our modular total synthesis method of leoligin, modifications at two positions were undertaken and the effects of these modifications on the biological activity were investigated. The first modification concerned the ester functionality, where it was found that variations in this position have a significant influence, with bulky esters lacking Michael-acceptor properties being favored. Additionally, the substituents on the aryl group in position 2 of the tetrahydrofuran scaffold can vary to some extent, where it was found that a 3,4-dimethoxy and a 4-fluoro substitution pattern show comparable inhibitory efficiency. MDPI 2021-12-28 /pmc/articles/PMC8773117/ /pubmed/35052742 http://dx.doi.org/10.3390/biomedicines10010062 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Linder, Thomas
Papaplioura, Eleni
Ogurlu, Diyana
Geyrhofer, Sophie
Hummelbrunner, Scarlet
Schachner, Daniel
Atanasov, Atanas G.
Mihovilovic, Marko D.
Dirsch, Verena M.
Schnürch, Michael
Investigation of Leoligin Derivatives as NF-κΒ Inhibitory Agents
title Investigation of Leoligin Derivatives as NF-κΒ Inhibitory Agents
title_full Investigation of Leoligin Derivatives as NF-κΒ Inhibitory Agents
title_fullStr Investigation of Leoligin Derivatives as NF-κΒ Inhibitory Agents
title_full_unstemmed Investigation of Leoligin Derivatives as NF-κΒ Inhibitory Agents
title_short Investigation of Leoligin Derivatives as NF-κΒ Inhibitory Agents
title_sort investigation of leoligin derivatives as nf-κβ inhibitory agents
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773117/
https://www.ncbi.nlm.nih.gov/pubmed/35052742
http://dx.doi.org/10.3390/biomedicines10010062
work_keys_str_mv AT linderthomas investigationofleoliginderivativesasnfkbinhibitoryagents
AT papapliouraeleni investigationofleoliginderivativesasnfkbinhibitoryagents
AT ogurludiyana investigationofleoliginderivativesasnfkbinhibitoryagents
AT geyrhofersophie investigationofleoliginderivativesasnfkbinhibitoryagents
AT hummelbrunnerscarlet investigationofleoliginderivativesasnfkbinhibitoryagents
AT schachnerdaniel investigationofleoliginderivativesasnfkbinhibitoryagents
AT atanasovatanasg investigationofleoliginderivativesasnfkbinhibitoryagents
AT mihovilovicmarkod investigationofleoliginderivativesasnfkbinhibitoryagents
AT dirschverenam investigationofleoliginderivativesasnfkbinhibitoryagents
AT schnurchmichael investigationofleoliginderivativesasnfkbinhibitoryagents